New HIV vaccine candidate enters early human testing

NCT ID NCT03934541

Completed ⭐️ VACCINE ⭐️ Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a new HIV vaccine in 24 healthy, HIV-negative adults. The vaccine uses a liposome (a tiny fat bubble) to deliver a piece of the HIV virus to the immune system. The main goal was to check if the vaccine is safe and whether it triggers an immune response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MPER-656 Liposome Vaccine
What this could lead to: If successful, this could pave the way for a vaccine that helps prevent HIV infection.
What could go wrong: This is a very early Phase 1 trial with only 24 people, focused on safety. It may not lead to an effective vaccine, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

Alabama CRS

Birmingham, Alabama, 35294, United States
Brigham and Women's Hospital Vaccine CRS (BWH VCRS)

Boston, Massachusetts, 02115-6110, United States
Columbia P&S CRS

New York, New York, 10032-3732, United States
Fenway Health (FH) CRS

Boston, Massachusetts, 02215-4302, United States
New York Blood Center CRS

New York, New York, 10065, United States
Seattle Vaccine and Prevention CRS

Seattle, Washington, 98109-1024, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.